A Clinical Study of SHR-9539 in Patients With Multiple Myeloma

Summary

This study is a multicenter, open-label, dose-escalation/dose-expansion clinical Phase I trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy profile of SHR-9539 Injection in patients with multiple myeloma.

Timeline

Start

2024-08-07

Primary completion

2027-07-31

Completion

2027-07-31

Drugs

Indications